Conduit Pharmaceuticals Book Value Per Share vs. Net Income
Market capitalization and book value offer complementary views of Conduit Pharmaceuticals — the first driven by investor sentiment, the second by accounting standards. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Conduit Pharmaceuticals are related but not identical, and they can diverge across cycles. For Conduit Pharmaceuticals, key inputs include revenue of 2.72 B. By contrast, market price reflects the level where buyers and sellers transact.
Conduit Pharmaceuticals Net Income vs. Book Value Per Share Fundamental Analysis
Peer-based valuation metrics position Conduit Pharmaceuticals within its sector hierarchy. Conduit Pharmaceuticals is rated below average for book value per share across the peer group. It stands at number one for net income across the peer group reflecting a 70,880,931 ratio of Net Income to Book Value Per Share. Book Value Per Share is evolving in line with broader financial reporting trends. Last year, Conduit Pharmaceuticals recorded Book Value Per Share of 31.93. Comparative earnings metrics contextualize Conduit Pharmaceuticals.Conduit Net Income vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Conduit Pharmaceuticals |
| = | 3.35 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Conduit Pharmaceuticals |
| = | 237.52 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Conduit Net Income Comparison
Conduit Pharmaceuticals is currently under evaluation for net income across the peer group.
Conduit Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Conduit Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Conduit Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Conduit Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Conduit Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -97.2 M | -92.3 M | |
| Operating Income | 315.7 M | 331.5 M | |
| Net Loss | -16 M | -15.2 M | |
| Income Before Tax | 266.9 M | 280.2 M | |
| Total Other Income Expense Net | -48.8 M | -46.4 M | |
| Net Income | 237.5 M | 249.4 M | |
| Income Tax Expense | -29.3 M | -27.9 M | |
| Net Interest Income | -1.3 M | -1.3 M | |
| Interest Income | 14.9 K | 15.8 K | |
| Net Income Per Share | 6.00 | 6.30 | |
| Income Quality | 1.49 | 2.81 | |
| Net Income Per E B T | 0.80 | 0.84 |
Conduit Profitability Driver Comparison
Profitability drivers for Conduit Pharmaceuticals are the financial and operational factors with the greatest impact on its earnings. Investors must anticipate a wide variety of external disruptions that can affect Conduit Pharmaceuticals' profit margins, market performance, and overall investment attractiveness.
Earnings per Share Projection vs Actual
Use Conduit Pharmaceuticals in pair-trading
Pair trading with Conduit Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Conduit Pharmaceuticals Pair Trading
Conduit Pharmaceuticals Pair Trading Analysis
The information in the correlation table below can inform Conduit Pharmaceuticals tax-loss harvesting decisions, showing which instruments historically move in lockstep with Conduit Pharmaceuticals and can serve as viable temporary replacements.
Negative correlation assets provide natural hedges against Conduit Pharmaceuticals positions. When Conduit Pharmaceuticals's value declines, a negatively correlated instrument tends to rise, partially offsetting portfolio losses.
Pair evaluation and Correlation analysis for Conduit Pharmaceuticals provide hedging context. This approach is commonly reviewed within sectors and across broader groups.Use Investing Themes to Complement your Conduit Pharmaceuticals position
Using Conduit Pharmaceuticals inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Did You Try This Idea?
Run Iron Thematic Idea Now
Iron
Companies involved in production of steel and iron. The Iron theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Iron Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Conduit Stock Analysis
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |